Nuvalent Inc Ordinary Shares - Class A NUVL 深 沪
已收盘 10-31 16:00:00 美东时间
99.32
+1.150
+1.17%
华盛通- 最 高100.77
- 今 开99.85
- 成交量 60.69万股
- 最 低 96.11
- 昨 收 98.17
- 总市值 71.61亿
- 52周最高 104.90
- 市盈率 静 --
- 换手率 0.84%
- 52周最低 55.535
- 委 比 71.95%
- 总股本 7210.48万
- 历史最高 113.51
- 量 比 0.68
- 振 幅 4.75%
- 历史最低 7.09
- 每 手 1
- 风险率 7.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nuvalent GAAP EPS of -$1.70
Nuvalent press release (NUVL): Q3 GAAP EPS of -$1.70. Cash, cash equivalents and marketable securities were $943.1 million as of September 30, 2025. Nuvalent continues to believe its existing cash, ca...
10-30 19:29
Earnings Scheduled For October 30, 2025
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
Nuvalent Q3 EPS $(1.70) Misses $(1.36) Estimate
Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(1.70) per share which missed the analyst consensus estimate of $(1.36) by 24.54 percent. This is a 32.81 percent decrease over losses of $(1.28) per share from the
10-30 18:38
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128
Piper Sandler analyst Kelsey Goodwin maintains Nuvalent (NASDAQ:NUVL) with a Overweight and raises the price target from $112 to $128.
10-27 21:13
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
Stifel Reinstates Buy on Nuvalent, Announces $115 Price Target
Stifel analyst Laura Prendergast reinstates Nuvalent (NASDAQ:NUVL) with a Buy and announces $115 price target.
10-16 21:54
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
Nuvalent To Present Preclinical Intracranial Activity Of HER2-Selective Inhibitor, NVL-330, At AACR-NCI-EORTC International Conference 2025
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming poster
10-14 00:55
Nuvalent Completes New Drug Application Submission
The latest update is out from Nuvalent ( ($NUVL) ). On September 22, 2025, Nuva...
09-22 18:58
